Innate Pharma (HAM:IDD) 1-Year Sharpe Ratio: N/A (As of Sep. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:IDD Innate Pharma SA HAM:IDD
35 GF Score
Price €1.78
GF Value €0.13
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Innate Pharma 1-Year Sharpe Ratio?

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-09-02), Innate Pharma's 1-Year Sharpe Ratio is Not available.

Innate Pharma  (HAM:IDD) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Innate Pharma 1-Year Sharpe Ratio Related Terms

HAM:IDD vs VRTX, REGN, MRNA: 1-Year Sharpe Ratio Comparison

For the Biotechnology subindustry, Innate Pharma's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innate Pharma 1-Year Sharpe Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innate Pharma's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Innate Pharma's 1-Year Sharpe Ratio falls into.


HAM:IDD
35GF Score
Innate Pharma SA HAM:IDD
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Innate Pharma 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Is Innate Pharma (HAM:IDD) Overvalued in 2026?

Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued. The current stock price of €1.78 is trading 1269.2% above its estimated GF Value™ of €0.13. GuruFocus considers Innate Pharma to be Significantly Overvalued.

Key valuation signals for HAM:IDD:

  • 1-Year Sharpe Ratio: N/A
  • GF Value™: €0.13 vs. price of €1.78 (1269.2% above fair value)
  • GF Score™: 35/100 with 8 warning signs

No single metric tells the full story. See the HAM:IDD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Innate Pharma Business Description

Address 117, Avenue de Luminy, Marseille, FRA, 13009
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
35GF Score

Get the complete analysis for HAM:IDD

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.78
Price
€0.13
GF Value